Weight loss medications can reduce half of the risk of inserting heart patients or death early, according to the largest study of its kind.
The category of medicines, known as the GLP-1 stimuli, is found to provide “exciting benefits” for heart patients, which greatly reduces the risk of seriously developing the disease or pre-ultra-death of any reason.
This discovery, which was revealed at the largest conference in the world in Madrid, means that they can be given millions of heart patients to help them stay outside the hospital and live for a longer period.
Weight loss drugs simulate the glucagon -like peptide (GLP), which makes people feel full, and was initially developed to treat diabetes. In recent years, evidence has emerged indicating that it may prove that it has saved life through a set of conditions that exceed obesity.
Now the results of the main new research, presented at the annual conference of the European Society of Heart Diseases, show that weight loss medications can reduce the risk of inserting heart diseases or early death by up to 58 %.
In the study, American researchers from Brigham, a non -profit network of doctors and hospitals in Boston, analyzed the real world data from more than 90,000 patients in obese heart failure and had type 2 diabetes. All of them were heart failure with a HFPEF, which is the most common form of the condition.
The results showed that those who took Smaglutide were 42 % less likely in the hospital or died prematurely, compared to an agent for delusive therapy. In the same study, Tirzepatide reduced the risk of hospitalization of heart failure or death from any 58 % cause.
Globally, more than 60 million people suffer from heart failure. Previous studies have indicated that weight loss medications may improve the symptoms of heart failure, but their effect on important results such as hospitalization and death has not been evaluated in a large number of population so far.
The results of the study presented in Madrid were published simultaneously at JAMA, the American Medical Association Magazine.
“Although the mortality and deaths are widely from HFPEF, the current treatment options are limited,” said Dr. Nils Kirger, of Brigham Hospital, Women’s Hospital, and a founding member of the comprehensive health care system for healthcare.
Smaglutide is famous for its effects on weight loss and blood sugar control, but our study indicates that it may also provide great benefits for obese and type 2 patients by reducing the results of harmful heart failure.
“The results we find that in the future, drugs that target GLP-1 can provide a treatment option that affects the need for patients with heart failure.”
The results add evidence that weight loss medications may help in treating or preventing heart disease.
In May, I found an experiment that people who take a poultryide suffer from 20 % lower risk of heart attack, stroke, or death due to cardiovascular disease. The University University study also found that the pillar that led to the benefits of the heart and blood vessels, regardless of the weight of a person or the amount of weight it lost.
Dr. Carlos Aguariar, Vice President of the European Society for Heart Diseases and a world -famous expert in heart failure, who did not participate in the study, welcomed the results.
“What indicates this is that there is a benefit in using one of these two factors, samilutide or tirzepatide, to reduce the risk of healing from heart failure or completely deaths.
))
Agueiar, Carne Cruise Hospital, Carnexide, Portugal, said that more evidence will be required before doctors recommend to rid weight loss medications to heart patients specifically to reduce the risk of harmful health results, but the results of the study were “good news”.
“This data adds to an increasing group of evidence that supports a role in weight loss medications for patients with heart failure and obesity, to reduce acceptance of the hospital and death,” said Dr. Sonia Babu Narayan, a consultant for heart disease and clinical director of the British Heart Foundation.
“It is very important that qualified heart failure patients have the opportunity to consider these treatments, as well as other evidence -based heart failure.”